Histopathological Changes in Mycosis Fungoides
Primary Purpose
Mycosis Fungoides
Status
Recruiting
Phase
Not Applicable
Locations
Turkey
Study Type
Interventional
Intervention
biopsy
Sponsored by
About this trial
This is an interventional diagnostic trial for Mycosis Fungoides focused on measuring mycosis fungoides, histopathology
Eligibility Criteria
Inclusion Criteria: Histopathologically confirmed mycosis fungoides stage 1A patients Exclusion Criteria: Mycosis fungoides patients with other stages
Sites / Locations
- Bezmialem Vakif University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Experimental
Arm Label
lesional skin
non-lesional skin
Arm Description
lesional skin of mycosis fungoides stage 1A patients
non-lesional skin of mycosis fungoides stage 1A patients
Outcomes
Primary Outcome Measures
CD4+ T cells in epidermis
Histopathologically clonal T lymphocytes in epidermis reveal the diagnosis. If they are seen in non-lesional skin, then lesional specific local treatment is not enough for the disease.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT05904522
Brief Title
Histopathological Changes in Mycosis Fungoides
Official Title
Evaluation of Histopathological Changes in the Non-lesional Skin of Stage 1A Mycosis Fungoides Patients
Study Type
Interventional
2. Study Status
Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 1, 2023 (Actual)
Primary Completion Date
October 31, 2023 (Anticipated)
Study Completion Date
October 31, 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Bezmialem Vakif University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
Patients with mycosis fungoides stage 1A disease have patch and plaque lesions less than %10 of body skin area. Aim of the study is to compare lesional and non-lesional skin of mycosis fungoides patients, and to decide if the systemic treatment is better or local treatment is better for them. Two biopsies for each patient were taken from lesional and non-lesional skin area.
Detailed Description
Patients with mycosis fungoides stage 1A disease have patch and plaque lesions less than %10 of body skin area. Aim of the study is to compare lesional and non-lesional skin of mycosis fungoides patients, and to decide if the systemic treatment is better or local treatment is better for them. Two biopsies for each patient were taken from lesional and non-lesional skin area.
Biopsies will be taken from lesional and non-lesional skin of the patients in the dermatology clinic and sent to laboratory for histopathologic examination.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Mycosis Fungoides
Keywords
mycosis fungoides, histopathology
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Biopsies will be taken from lesional and non-lesional skin of the patients in the dermatology clinic and sent to laboratory for histopathologic examination. Lesional skin of the patient will be compared with the non-lesional skin of the same patient.
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
lesional skin
Arm Type
Experimental
Arm Description
lesional skin of mycosis fungoides stage 1A patients
Arm Title
non-lesional skin
Arm Type
Experimental
Arm Description
non-lesional skin of mycosis fungoides stage 1A patients
Intervention Type
Diagnostic Test
Intervention Name(s)
biopsy
Intervention Description
biopsy for histopathological examination
Primary Outcome Measure Information:
Title
CD4+ T cells in epidermis
Description
Histopathologically clonal T lymphocytes in epidermis reveal the diagnosis. If they are seen in non-lesional skin, then lesional specific local treatment is not enough for the disease.
Time Frame
6 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
100 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Histopathologically confirmed mycosis fungoides stage 1A patients
Exclusion Criteria:
Mycosis fungoides patients with other stages
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Ömer Mert
Phone
+905396778884
Email
omermert95@gmail.com
Facility Information:
Facility Name
Bezmialem Vakif University Hospital
City
Istanbul
Country
Turkey
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Ömer Mert
Phone
+905396778884
Email
omermert95@gmail.com
First Name & Middle Initial & Last Name & Degree
Ömer Mert
First Name & Middle Initial & Last Name & Degree
Özlem Su Küçük
12. IPD Sharing Statement
Learn more about this trial
Histopathological Changes in Mycosis Fungoides
We'll reach out to this number within 24 hrs